Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the...Clinical Collaboration Agreement • November 13th, 2018 • Cyclacel Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
This Clinical Collaboration Agreement (“Agreement”), effective as of the 21 day of August, 2018 (“Effective Date”), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”) and Cyclacel Limited, with a place of business located at 1 James Lindsay Place, Dundee, Scotland, DD1 5JJ, United Kingdom, (“Cyclacel”) (MD Anderson and Cyclacel each a “Party,” and collectively, the “Parties”).
